相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Polymer-lipid hybrid nanovesicle-enabled combination of immunogenic chemotherapy and RNAi-mediated PD-L1 knockdown elicits antitumor immunity against melanoma
Changrong Wang et al.
BIOMATERIALS (2021)
Beyond Blocking: Engineering RNAi-Mediated Targeted Immune Checkpoint Nanoblocker Enables T-Cell-lndependent Cancer Treatment
Xiaoyan Han et al.
ACS NANO (2020)
Carrier-free nanoassembly of doxorubicin prodrug and siRNA for combinationally inducing immunogenic cell death and reversing immunosuppression
Senbiao Chen et al.
NANO TODAY (2020)
Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer
Bo Gong et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2019)
Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory
Mauro Poggio et al.
CELL (2019)
Doxorubicin and siRNA-PD-L1 co-delivery with T7 modified ROS-sensitive nanoparticles for tumor chemoimmunotherapy
Wen-jun Wan et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2019)
Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
Jun Wang et al.
CELL (2019)
Immune checkpoint blockade opens a new way to cancer immunotherapy
Sanam Sadreddini et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Jonathan J. Havel et al.
NATURE REVIEWS CANCER (2019)
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Gang Chen et al.
NATURE (2018)
Nanoparticles as carriers for drug delivery in cancer
Ankita Dadwal et al.
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY (2018)
Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer
Ruea-Yea Huang et al.
ONCOIMMUNOLOGY (2017)
A ROS-responsive polymeric micelle with a π-conjugated thioketal moiety for enhanced drug loading and efficient drug delivery
Changzhen Sun et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2017)
Coadministration of Oligomeric Hyaluronic Acid-Modified Liposomes with Tumor-Penetrating Peptide-iRGD Enhances the Antitumor Efficacy of Doxorubicin against Melanoma
Caifeng Deng et al.
ACS APPLIED MATERIALS & INTERFACES (2017)
Emerging Opportunities and Challenges in Cancer Immunotherapy
Theresa L. Whiteside et al.
CLINICAL CANCER RESEARCH (2016)
Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation
Shi-Yong Li et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade
Kristen E. Pauken et al.
SCIENCE (2016)
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
A Novel Strategy through Combining iRGD Peptide with Tumor-Microenvironment-Responsive and Multistage Nanoparticles for Deep Tumor Penetration
Xingli Cun et al.
ACS APPLIED MATERIALS & INTERFACES (2015)
Enhancing cancer targeting and anticancer activity by a stimulus-sensitive multifunctional polymer-drug conjugate
Ying Tu et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Bioresponsive polymeric nanotherapeutics for targeted cancer chemotherapy
Ru Cheng et al.
NANO TODAY (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
Immune evasion in cancer: Mechanistic basis and therapeutic strategies
Dass S. Vinay et al.
SEMINARS IN CANCER BIOLOGY (2015)
Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma
Liang Wang et al.
ONCOTARGET (2015)
Ovarian Cancer Immunotherapy Using PD-L1 siRNA Targeted Delivery from Folic Acid-Functionalized Polyethylenimine: Strategies to Enhance T Cell Killing
Pei Yun Teo et al.
ADVANCED HEALTHCARE MATERIALS (2015)
Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2015)
pH-Sensitive nano-systems for drug delivery in cancer therapy
Juan Liu et al.
BIOTECHNOLOGY ADVANCES (2014)
Nanoparticles in drug delivery: Past, present and future
P. Couvreur
ADVANCED DRUG DELIVERY REVIEWS (2013)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
The benefits and challenges associated with the use of drug delivery systems in cancer therapy
Edna Cukierman et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs
Kazuki N. Sugahara et al.
SCIENCE (2010)
Selective Filtering of Particles by the Extracellular Matrix: An Electrostatic Bandpass
Oliver Lieleg et al.
BIOPHYSICAL JOURNAL (2009)
Adaptive immunity maintains occult cancer in an equilibrium state
Catherine M. Koebel et al.
NATURE (2007)
PD-1 and PD-1 ligands: from discovery to clinical application
Taku Okazaki et al.
INTERNATIONAL IMMUNOLOGY (2007)
分享论文
